{
    "id": "dbpedia_1360_1",
    "rank": 56,
    "data": {
        "url": "https://www.unisr.it/en/docenti/g/giustina-andrea",
        "read_more_link": "",
        "language": "en",
        "title": "Giustina Andrea",
        "top_image": "https://www.unisr.it/mediaObject/unisr/imported/docenti/uploads/2017/01/GIUSTINA/original/GIUSTINA.jpg",
        "meta_img": "https://www.unisr.it/mediaObject/unisr/imported/docenti/uploads/2017/01/GIUSTINA/original/GIUSTINA.jpg",
        "images": [
            "https://www.unisr.it/docroot/1.7.0/unisr/dist/images/logo_global.svg",
            "https://www.unisr.it/docroot/1.7.0/unisr/dist/images/logo_global.svg",
            "https://www.unisr.it/docroot/1.7.0/unisr/dist/images/logo_global.svg",
            "https://www.unisr.it/mediaObject/unisr/imported/docenti/uploads/2017/01/GIUSTINA/resolutions/res-c323x323/GIUSTINA.jpg",
            "https://www.unisr.it/mediaObject/unisr/home-page/media-new/newsletter3-2-/resolutions/res-c760x540/newsletter3-2-.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "",
        "meta_favicon": "/docroot/1.7.0/unisr/favicons/apple-touch-icon.png?v=ng9886WLv9",
        "meta_site_name": "",
        "canonical_link": "https://www.unisr.it/en/docenti/g/giustina-andrea",
        "text": "1988\n\n1) Development of type II autoimmune polyglandular syndrome in a patient with idiopathic thrombocytopenic purpura.\n\nR. Candrina, A. Giustina\n\nIsrael Journal of Medical Sciences, 24: 57-58, 1988.\n\n2) Low dose acyclovir and acute renal failure.\n\nA. Giustina, G. Romanelli, A. Cimino, G. Brunori\n\nAnnals of Internal Medicine, 108: 312, 1988.\n\n3) Growth hormone deficiency rapidly reversible during glucocorticoid replacement in a case of adrenocorticotropin deficiency.\n\nA. Giustina, R. Candrina, G. Romanelli\n\nThe Netherlands Journal of Medicine, 33: 219-297, 1988.\n\n4) Development of isolated ACTH deficiency in a man with type I diabetes mellitus.\n\nA. Giustina, R. Candrina, A. Cimino, G. Romanelli\n\nJournal of Endocrinological Investigation, 11: 375-377, 1988.\n\n1989\n\n5) Effects of benfluorex on glucose tolerance, metabolic control, beta-cell secretion, and peripheral sensitivity to insulin in obese type II diabetic patients on a body-weight maintaining diet.\n\nA. Giustina, L. Rocca, G. Romanelli, F. Zuccato, G. Giustina.\n\nCurrent Therapeutic Research, 45: 33-42, 1989.\n\n6) Effect of age on beta-cell response to glucagon in man.\n\nA. Giustina, P. Cravarezza, G. Romanelli, S. Spandrio, F. Zuccato.\n\nHormone and Metabolic Research, 21: 277-279, 1989.\n\n7) Short-term effect of captopril on microalbuminuria in¬duced by exercise in normotensive diabetics.\n\nG. Romanelli, A. Giustina, A. Cimino, U. Valentini, E. Agabiti-Rosei, G. Muiesan, G. Giustina.\n\nBritish Medical Journal, 298: 284-288, 1989.\n\n8) Effects of intranasal calcitonin administration on pituitary GH response to GHRH (1-29)NH2 in normal adult subjects.\n\nA. Giustina, M. Doga, G. Pizzocolo, G. Romanelli, G. Giustina.\n\nClinical Endocrinology, 30: 699-704, 1989.\n\n9) Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocor¬ticoid replacement.\n\nA. Giustina, R. Candrina, G. Romanelli, G. Giustina.\n\nJournal of Clinical Endocrinology and Metabolism, 68: 120-124, 1989.\n\n10) Growth hormone response to thyrotropin releasing hor¬mone and placebo in a group of insulin dependent diabetic patients.\n\nU. Valentini, A. Cimino, A. Rotondi, L. Rocca, R. Pelizzari, A. Giustina, C. Marchetti, G. Romanelli\n\nJournal of Endocrinological Investigation, 12: 643-646, 1989.\n\n11) Effects of short-term glucocorticoid deprivation on growth hormone (GH) response to GH-releasing hormone in man.\n\nA. Giustina, G. Romanelli, S. Bossoni, A. Girelli, G. Pizzocolo, U. Valentini, F. Zuccato\n\nHormone and Metabolic Research, 21:693-4, 1989.\n\n1990\n\n12) Acute effects of cortisone acetate on growth hormone (GH) response to GH-releasing hormone in normal adult subjects.\n\nA. Giustina, M. Doga, C. Bodini, A. Girelli, F. Legati, S. Bossoni, G. Romanelli\n\nActa Endocrinologica (Copenaghen), 122: 206-210, 1990.\n\n13) A single dose of aztreonam in the prevention of urinary tract infections in elderly catheterized patients.\n\nG. Romanelli, A. Giustina, S. Bossoni, A. Caldonazzo, P. Cravarezza, F. Zuccato, A. Turano\n\nJournal of Chemotherapy, 2: 178-183, 1990.\n\n14) Pyridostigmine blocks the inhibitory effects of glucocorticoids on growth hormone releasing hormone stimulated growth hormone secretion in man.\n\nA. Giustina, A. Girelli, M. Doga, C. Bodini, S. Bossoni, G. Romanelli, W.B. Wehrenberg\n\nJournal of Clinical Endocrinology and Metabolism, 71: 580-5, 1990.\n\n15) Effects of calcitonin on GH response to pyridostigmine in combination with GHRH (1-29)NH2 in normal adult subjects.\n\nA. Giustina, C. Bodini, S. Bossoni, M. Doga, A. Girelli, G. Pizzocolo, W.B. Wehrenberg.\n\nClinical Endocrinology, 33: 375-380, 1990.\n\n16) Short term administration of captopril and nifedipine and exercise induced albuminuria in normotensive diabetic patients with early stage nephropathy.\n\nG. Romanelli, A. Giustina, S. Bossoni, A. Caldonazzo, A. Cimino, P. Cravarezza, G. Giustina\n\nDiabetes, 39: 1333-1338, 1990.\n\n17) Central alpha-2 adrenergic function in patients with essential hypertension. Comparative study of growth hormone (GH) secretion stimulated by clonidine and GH-releasing hormone.\n\nA. Giustina, M. Doga, S. Bossoni, C. Bodini, F. Legati, G. Pizzocolo, G. Romanelli\n\nHormone and Metabolic Research, 22: 451-452, 1990\n\n18) Mechanisms of calcitonin-induced suppression of the growth hormone (GH) response to GH-releasing hormone in nor¬mal men. Role of somatostatin.\n\nA. Giustina, M. Doga, S. Bossoni, A. Girelli, G. Pizzocolo, W.B. Wehrenberg\n\nJournal of Endocrinological Investigation, 13 (Suppl. 2): 111, 1990.\n\n19) Impaired growth hormone (GH) response to pyridostig¬mine in type 1 diabetic patients with exaggerated GH-releasing hormone stimulated GH secretion\n\nA. Giustina, S. Bossoni, A. Cimino, G. Pizzocolo, G. Romanelli, W.B. Wehrenberg\n\nJournal of Clinical Endocrinology and Metabolism, 71: 1486-1450, 1990.\n\n20) Effects of methimazole treatment on growth hormone (GH) response to GH-releasing hormone in patients with hyperthyroidism.\n\nA. Giustina, C. Ferrari, C. Bodini, M.G. Buffoli, F. Legati, M. Schettino, F. Zuccato, W.B. Wehrenberg\n\nActa Endocrinologica, 123: 613-619, 1990.\n\n21) Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies.\n\nW.B. Wehrenberg, P.J. Bergman, L. Stagg, J. Ndon, A. Giustina\n\nEndocrinology, 127: 2705-2708, 1990.\n\n1991\n\n22) Role of the cholinergic tone in the modulation of the dose-response curve of growth hormone-releasing hormone in¬duced growth hormone secretion in normal man.\n\nA. Giustina, S. Bossoni, C. Bodini,, M. Doga, A. Girelli, M.G. Buffoli, M. Schettino, W.B. Wehrenberg\n\nMetabolism, 40: 519-523, 1991\n\n23) Low-dose octreotide is able to cause a maximal inhibi¬tion of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin.\n\nA. Giustina, A. Girelli, M. G. Buffoli, A. Cimino, F. Legati, U. Valentini, G. Giustina\n\nDiabetes Research and Clinical Practice, 14: 47-54, 1991\n\n24) Effects of pyridostigmine on spontaneous and growth hormone-releasing hormone stimulated growth hormone secre¬tion in children on daily glucocorticoid treatment after liver transplantantion.\n\nA. Giustina, A. Girelli, D. Alberti, S. Bossoni, F. Buzi, M. Doga, M. Schettino, W.B. Wehrenberg\n\nClinical Endocrinology, 1991; 35: 491-498\n\n25) Albuminuria induced by exsercise in hypertensive type I and type II diabetic patients: a randomised, double-blind study on the effects of acute administration of captopril and nifedipine.\n\nG. Romanelli, A. Giustina, P. Cravarezza, A. Caldonazzo, M.L. Muiesan, E. Agabiti-Rosei\n\nJournal of Human Hypertension, 5: 167-173, 1991\n\n26) Acute effect of propranolol on the growth hormone (GH) response to GH-releasing hormone in patients with hyperthyroidism.\n\nA. Giustina, M.G. Buffoli, C. Ferrari, N. Gazzoli, G. Pizzocolo, C. Tassi, W.B. Wehrenberg\n\nHormone Metabolic Research, 23: 461-514, 1991.\n\n27) Effect of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostig¬mine in type I diabetic patients.\n\nA. Giustina, S. Bossoni, C. Bodini, A. Cimino, G. Pizzocolo, M. Schettino, W.B. Wehrenberg\n\nActa Endocrinologica, 125: 510-517, 1991\n\n28) Acute effect of clonidine and growth hormone (GH)-releasing hormone on GH secretion in patients with hypertyroidism.\n\nA. Giustina, M.G. Buffoli, A.R. Bussi, W.B. Wehrenberg.\n\nHormone Research, 36:192-195, 1991\n\n1992\n\n29) Effect of galanin on growth hormone (GH)-releasing hormone stimulated GH secretion in adult patients with nonendocrine diseases on long-term daily glucocorticoid treatment.\n\nA. Giustina, A. Girelli, S. Bossoni, F. Legati, M. Schettino, W.B. Wehrenberg.\n\nMetabolism, 41:548-551, 1992\n\n30) Thyrotropin and prolactin secretion are not affected by porcine and rat galanin in normal subjects.\n\nA. Giustina, A. Girelli, M. Licini, M. Schettino, A. Negro-Vilar.\n\nHormone and Metabolic Research, 24:351-352, 1992\n\n31) Hypothalamic regulation of impaired growth hormone secretion in diabetic rats. 1: Studies on streptozotocin-induced diabetic rats.\n\nJ.A. Ndon, A. Giustina, W.B. Wehrenberg.\n\nNeuroendocrinology, 55:500-505, 1992\n\n32) Hypothalamic regulation of impaired growth hormone secretion in diabetic rats. 2: Studies in spontaneously diabetic BB Worcester rat.\n\nJ.A. Ndon, A. Giustina, W.B. Wehrenberg.\n\nNeuroendocrinology, 55:506-511, 1992\n\n33) Acute effect of hydrocortisone on circulating growth hormone levels in patients with acromegaly.\n\nA. Giustina, A.R. Bussi, M. Licini, G. Pizzocolo, M. Schettino, W.B. Wehrenberg.\n\nHormone Research, 37:212-216, 1992\n\n34) Comparative effect of galanin and pyridostigmine on the growth hormone (GH) response to GH-releasing hormone in normal aged subjects.\n\nA. Giustina, A.R. Bussi, C. Conti, M. Doga, F. Legati, C. Macca, F. Zuccato, W.B. Wehrenberg.\n\nHormone Research, 37:165-170, 1992\n\n35) The role of glucocorticoids in the regulation of growth hormone secretion. Mechanisms and clinical significance.\n\nA. Giustina, W.B. Wehrenberg.\n\nTrends in Endocrinology and Metabolism, 3:306-311, 1992\n\n36) Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy.\n\nA. Giustina, S. Bossoni, C. Bodini, A. Girelli, G.P. Balestrieri, G. Pizzocolo, W.B. Wehrenberg.\n\nJournal of Clinical Endocrinology and Metabolism, 74:1301-1305, 1992\n\n37) Galanin decreases circulating growth hormone levels in acromegaly.\n\nA. Giustina, C. Bodini, M. Doga, M. Schettino, G. Pizzocolo, G. Giustina.\n\nJournal of Clinical Endocrinology and Metabolism, 74:1296-1300, 1992\n\n38) Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in acromegaly.\n\nA. Giustina, M. Schettino, C. Bodini, M. Doga, G. Giustina.\n\nMetabolism, 41:1291-1294, 1992\n\n39) Basic counterpoint: mechanisms and pathways of gonadal steroid modulation of growth hormone secretion.\n\nW.B. Wehrenberg, A. Giustina.\n\nEndocrine Reviews, 13:299-308, 1992\n\n40) Pyridostigmine-mediated growth hormone release: evidence for somatostatin involvment.\n\nW.B. Wehrenberg, S.D. Wiviott, D.M. Voltz, A. Giustina.\n\nEndocrinology, 130:1445-1450, 1992\n\n41) Comparative effect of porcine and rat galanin on growth hormone secretion in normal adult men.\n\nA. Giustina. A. Girelli, C. Bodini, M. Doga, M. Schettino, A. Negro-Vilar.\n\nHormone and Metabolic Research, 24:90-91, 1992\n\n42) Effect of pretreatment with pyridostigmine on the thyrotropin response to thyrotropin-releasing hormone in patients with Cushing’s disease.\n\nA. Giustina, S. Bossoni, M.G. Buffoli, C. Ferrari, A. Pozzi, T. Scalvini, M. Schettino.\n\nHormone and Metabolic Research, 24:248-250, 1992\n\n43) Comparative effect of clonidine and growth hormone (GH)-releasing hormone on GH secretion in adult patients on chronic glucocorticoid therapy.\n\nA. Giustina, M.G. Buffoli, A.R. Bussi, M. Doga, A. Girelli, G. Pizzocolo, A.Pozzi,W.B. Wehrenberg.\n\nHormone and Metabolic Research, 24:240-243, 1992\n\n44) Galanin does not affect the growth hormone (GH)-releasing hormone-stimulated GH secretion in patients with hyperthyroidism.\n\nA. Giustina, A.R. Bussi, F. Legati, S. Bossoni, M. Licini, M. Schettino, F. Zuccato, W.B. Wehrenberg.\n\nActa Endocrinologica, 127:504-508, 1992\n\n45) Effect of arginine on the growth hormone (GH)-releasing hormone stimulated GH-secretion in patients with hyperthyroidism.\n\nA. Giustina, M. Schettino, A.R. Bussi, F. Legati, M. Licini, F. Zuccato, W.B. Wehrenberg.\n\nHormone Research, 38:256-259, 1992\n\n1993\n\n46) Picotamide, a dual TXB Synthetase inhibitor and TXB Receptor antagonist, reduces exercise-induced albuminuria in microalbuminuric patients with NIDDM.\n\nA. Giustina, S. Bossoni, A. Cimino, M.T. Comini, N. Gazzoli, G.B. Leproux, W.B. Wehrenberg, G. Romanelli, G. Giustina.\n\nDiabetes;42:178-182, 1993\n\n47) Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing’s disease.\n\nA. Giustina, S. Bossoni, A.R. Bussi, A. Pozzi, W.B. Wehrenberg.\n\nEndocrine Research, 19:47-56, 1993\n\n48) Effects of sex and age on the growth hormone response to galanin in healthy human subjects.\n\nA. Giustina, M. Licini, A.R. Bussi, A. Girelli, G. Pizzocolo, M. Schettino, A. Negro-Vilar.\n\nJournal of Clinical Endocrinology and Metabolism; 76:1369-1372, 1993\n\n49) Effect of galanin, and arginine, alone or in combination on growth hormone secretion in adult patients treated with glucocorticoids.\n\nA. Giustina, M. Licini, A. Girelli, A.R. Bussi, W.B. Wehrenberg.\n\nNeuroendocrinology; 57:843-848, 1993\n\n50) Isradipine decreases exercise-induced albuminuria in patients with essential hypertension.\n\nA. Giustina, S. Bossoni, C. Macca, G. Romanelli.\n\nRenal Failure; 15:509-514, 1993\n\n51) Effect of long-term treatment with bromocriptine on the growth hormone response to galanin in patients with acromegaly.\n\nA. Giustina, M. Doga, A.R. Bussi, M. Licini, M. Schettino.\n\nActa Endocrinologica; 128:131-135, 1993\n\n52) Hypothalamic regulation of growth hormone secretion during food deprivation in the rat.\n\nB.A. Janowski, N.C. Ling, A. Giustina, W.B. Wehrenberg.\n\nLife Sciences; 52:981-987, 1993\n\n53) The biological potency of equimolar amounts of somatostatin-14 and somatostatin-28 in rats.\n\nD.M. Volts, A. Giustina, R.C. Gaillard, W.B. Wehrenberg.\n\nEndocrine Journal; 1:235-239, 1993\n\n54) Effects of metoclopramide on the paradoxical growth hormone response to galanin in acromegaly.\n\nA. Giustina, M. Doga, C. Bodini, S. Bossoni, E. Bresciani, A.R. Bussi.\n\nEndocrine Research; 19:303-315, 1993\n\n55) Variability in the growth hormone response to growth hormone releasing hormone alone or combined with pyridostigmine in type 1 diabetic patients.\n\nA. Giustina, C. Bodini, S. Bossoni, U. Valentini, W.B. Wehrenberg.\n\nJournal of Endocrinological Investigation; 16:585-590, 1993\n\n56) Effects of metoclopramide on the growth hormone response to galanin in normal man.\n\nA. Giustina, A.R. Bussi, M. Doga, M. Licini, M. Schettino, W.B. Wehrenberg.\n\nHormone and Metabolic Research; 25:457-506, 1993\n\n57) Arginine blocks the inhibitory effects of hydrocortisone on circulating growth hormone levels in patients with acromegaly.\n\nA. Giustina, M. Schettino, S. Bossoni, A.R. Bussi, M. Doga, M. Licini, W.B. Wehrenberg.\n\nMetabolism,42:664-668,1993\n\n1994\n\n58) Physiological role of galanin in the regulation of anterior pituitary function in humans.\n\nA. Giustina, M. Licini, M. Schettino, M. Doga, G. Pizzocolo, A. Negro-Vilar.\n\nAmerican Journal of Physiology, 266:(29) E57-E61, 1994\n\n59) Acute effects of octreotide, a long-acting somatostatin analog, on insulinemic and glycemic response to a mixed meal in patients with essential obesity. A. dose-response study.\n\nA. Giustina, A.R. Bussi, G. Pizzocolo, A. Cimino, G. Giustina.\n\nDiabetes Nutrition and Metabolism, 7:35-41, 1994\n\n60) Growth hormone neuroregulation in diabetes mellitus.\n\nA. Giustina, W.B. Wehrenberg.\n\nTrends in Endocrinology and Metabolism, 5:73-78, 1994\n\n61) Effect of long-term administration of picotamide on baseline and exercise-induced urinary albumin excretion in patients with type II diabetes mellitus and incipient nephropathy.\n\nA. Giustina, P. Ianniello, S. Bossoni, M.T. Comini, P. Desenzani, N. Gazzoli, G. Romanelli.\n\nClinical Therapeutics, 16:191-199, 1994\n\n62) Effect of hydrocortisone on the growth hormone (GH) response to GH-releasing hormone in acromegaly.\n\nA. Giustina, A.R. Bussi, M. Doga, W.B. Wehrenberg.\n\nHormone Research, 41:33-37, 1994\n\n63) Acute and chronic effect of systemic administration of interleukin-1B and endotoxin on the hypothalamic-pituitary adrenal axis in the rat.\n\nW.B. Wehrenberg, P. Saudan, R. Corder, D.M. Voltz, A. Giustina, R.C. Gaillard.\n\nEndocrine Journal, 2:273-277, 1994\n\n64) Effect of galanin on the growth hormone (GH) response to thyrotropin-releasing hormone (TRH) in patients with acromegaly.\n\nA. Giustina, A.R. Bussi, E. Bresciani, M. Doga, M. Licini, M. Schettino, G. Giustina.\n\nNeuroendocrinology Letters, 16:151-158\n\n65) Hexarelin (His-D-2Methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), a new GH-releasing peptide, is biologically active in male and female rats.\n\nL.K. Conley, A. Giustina, B.P. Imbimbo, L.C. Stagg, R. Deghenghi, W.B. Wehrenberg.\n\nEndocrine Journal, 2: p. 691-695, 1994\n\n66) Effect of the combined administration of galanin and clonidine on serum growth hormone levels in normal subjects and in patients under chronic glucocorticoid treatment.\n\nA. Giustina, S. Bossoni, M. Licini, C. Macca, G. Milani, W.B. Wehrenberg.\n\nEndocrine Research, 20:151-164, 1994\n\n67) Effect of pyridostigmine on the growth hormone response to growth hormone-releasing hormone in lean and obese type II diabetic patients.\n\nA. Giustina,, E. Bresciani, C. Tassi, A. Girelli, U. Valentini.\n\nMetabolism.Vol 43 (7) p. 893-898. 1994.\n\n68) Reciprocal relationships between the level of circulating cortisol and the growth hormone responsiveness to growth hormone releasing hormone in man. Studies in hypoadrenal patients.\n\nA. Giustina, E. Bresciani, S. Bossoni, M. Doga, V. Misitano, W.B. Wehrenberg.\n\nJournal of Clinical Endocrinological and Metabolism. Vol. 79 (5) p 1266-1272. 1994.\n\n69) Serum lipoprotein(a) is not increased in niddm patients with microalbuminuria.\n\nA. Girelli, A. Cimuno, L. Rocca, A. salvi, S. Spandrio, U. Valentini, A. Giustina.\n\nDiabetes Care. Vol. 17 (5) p. 456-457. 1994.\n\n70) Effects of pirydostigmine on the hydrocortisone-mediated decrease of circulating growth hormone levels in acromegaly.\n\nA. Giustina, A.R. Bussi, M. Doga, C. Iacobello,W.B. Wehrenberg.\n\nHormone and Metabolic Research Vol 26, (6) p. 288-392. 1994.\n\n71) Effects of beta2-agonist during cardiopolmonary exercise test in COPD patients.\n\nM. Malerba, E. Boni, G. Romagnoni, B. Filippi, A. Politi, A. Giustina, C. Tantucci, V. Grassi.\n\nMonaldi Archives of Chest Diseases, 49: 389-393, 1994\n\n72) Inhibitory effect of galanin on growth hormone releases from rat pituitary tumor cells (GH1) in culture.\n\nA. Giustina, C. Bonfanti, M. Licini, C. De Rango, G. Milani.\n\nLife Sciences, 55: p. 1845-1851, 1994\n\n1995\n\n73) Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone.\n\nA. Giustina, A.R. Bussi, C. Jacobello and W.B. Wehrenberg.\n\nJournal of Clinical Endocrinology and Metabolism, 80: 122-129, 1995\n\n74) Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly.\n\nA. Giustina, E. Bresciani, A.R. Bussi, A. Bollati, C. Bonfanti, G. Bugari, L. Chiesa and G. Giustina.\n\nJournal of Clinical Endocrinology and Metabolism, 80: 1333-1340, 1995\n\n75) Changes in the growth hormone axis due exercise training in male and female rats: secretory and molecular responses.\n\nJ.A. Butkus, R.S. Brogan, A. Giustina, G. Kastello, M.Sothmann and W.B. Wehrenberg.\n\nEndocrinology, 36: 2664-2670, 1995\n\n76) Cardiopulmonary adaptation to exercise after acute weight loss in severely obese subjects.\n\nE. Boni, A. Giustina, E. Borra, A.R. Bussi, V. Grassi.\n\nMonaldi Archives of Chest Disease, 50: 264-268, 1995\n\n77) Hexarelin, a novel GHRH-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly.\n\nA. Giustina, E. Bresciani, G. Bugari, A.R. Bussi, R. Deghenghi, B. Imbimbo, G. Giustina.\n\nEndocrine Research, 21: 569-582, 1995\n\n78) Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers.\n\nB.P. Imbimbo, M. Licini, M. Schettino, A. Mosca, E. Onelli, L. Zecca, A. Giustina.\n\nThe Journal of Clinical Pharmacology, 35: 285-290,1995\n\n79) Effect of glucocorticoids on the paradoxical growth hormone response to thyrotropin-releasing hormone in patients with acromegaly.\n\nA. Giustina, M. Doga, E. Bresciani, A.R. Bussi, L. Chiesa, V. Misitano and G. Giustina.\n\nMetabolism, 44: 379-383, 1995\n\n80) Adrenergic and cholinergic involvement in basal and growth hormone-releasing hormone-stimulated growth hormone secretion in glucocorticoid-treated rats.\n\nA. Giustina, V. Misitano, D. Voltz, A. Piering, W.B. Wehrenberg.\n\nEndocrine Research, 21: 719-732, 1995\n\n81) Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in human with or without glucocorticoid excess.\n\nA. Giustina, A.R. Bussi, R. Deghenghi, B. Imbimbo, M. Licini, C. Poiesi, W.B. Wehrenberg.\n\nJournal of Endocrinology, 146: 2227-2232, 1995\n\n82) Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide.\n\nA. Giustina, E. Boni, G. Romanelli, V. Grassi, G. Giustina.\n\nThe American Journal of Cardiology, 75: 1042-1047, 1995\n\n83) Role of galanin in the regulation of somatotrope and gonadotrope function in young ovulatory women.\n\nA. Giustina, C. Gastaldi, G. Bugari, L. Chiesa, G. Loda, C. Tironi, A. Negro-Vilar.\n\nMetabolism, 44: 1028-1032, 1995\n\n84) Effect of two B2-agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis.\n\nA. Giustina, M. Malerba, E. Bresciani, P. Desenzani, M. Licini, G. Zaltieri and V. Grassi.\n\nJournal of Endocrinological Investigation, 18:847-852, 1995\n\n85) Influence of thyroid hormones on the regulation of growth hormone secretion.\n\nA. Giustina and W.B. Wehrenberg.\n\nEuropean Journal of Endocrinology, 133: 646-653, 1995\n\n86) Galanin countercts the inhibitory effects of glucocorticoids on growth hormone secretion in the rat.\n\nA. Giustina, D.M.Voltz, J. Teik, W.B. Wherenberg.\n\nMetabolism, Vol 44, (2), p.224-227. 1995.\n\n87) Effect of GHRP-6 and GHRH on GH secretion in rats following chronic glucocorticoid treatment.\n\nD.M.Voltz, A.W. Piering, M. Magestro, A. Giustina, W.B. Wherenberg.\n\nLife Sci. Vol.56, (7), p. 491-497. 1995.\n\n88) Mechanism of action of hexsarelin and GHRP-6: analysis of the involvment of GHRH and somatostatin in the rat.\n\nL.K. Conley, J.A. Teik, R. Deghenghi, B.P. Imbimbo, A. Giustina, V. Locatelli, W.B. Wherenberg.\n\nNeuroendocrinology. Vol. 61, (1) p. 44-50. 1995.\n\n1996\n\n89) Impaired spontaneous growth hormone secretion in severe dilated cardiomyopaty.\n\nA. Giustina, R. Lorusso, V. Borghetti, G. Bugari, V. Misitano and O. Alfieri.\n\nAmerican Heart Journal, 131/3: 629-622, 1996\n\n90) Effect of galanin on growth hormone (GH) response to thyrotropin releasing hormone of rat pituitary GH-secreting adenomatous cells (GH1) in culture.\n\nA. Giustina, C. Bonfanti, M. Licini, B. Stefana, G. Ragni, A. Turano.\n\nLife Sciences, 58: 83-90, 1996\n\n91) Immunocytochemical and molecular analysis of the effects of glucocorticoid treatment on the hypothalamic-somatotropic axis in the rat.\n\nS.K. Fife, R.S. Brogan, A. Giustina, W.B. Wehrenberg.\n\nNeuroendocrinology, 64:131-138, 1996.\n\n92) Hypothalamic control of GH secretion in type 1 diabetic men: effect of the combined administration of growth hormone (GH)-releasing hormone and Hexarelin, a novel GHRP-6 analog.\n\nA. Giustina, P. Desenzani, P. Perini, R. Deghenghi, G. Bugari, W.B. Wehrenberg, G. Giustina.\n\nEndocrine Research, 22:159-174, 1996.\n\n93) The Pharmacological Aspects Of The Treatment Of Acromegaly.\n\nA. Giustina, G. Zaltieri, F. Negrini, and W.B.Wehrenberg.\n\nPharmacological Research,Vol.34, p.247-268, 1996.\n\n1997\n\n94) Glutamate Decarboxylae Autoimmunity and Growth Hormone Secretion in Type I Diabetes Mellitus.\n\nA. Giustina, P. Desenzani, P. Perini, E. Bazzigaluppi, C. Bodini, S. Bossoni, C. Poiesi, W. B. Wehrenberg, and E. Bosi.\n\nMetabolism, Vol. 46, N. 4, p. 382-387, 1997.\n\n95) Inhibitory Effects of Galanin on Growth Hormone (GH) Release in Cultured GH-Secreting Adenoma Cells: Comparative Study With Octreotide, GH-Releasing Hormone, and Thyrotropin-Releasing Hormone.\n\nA. Giustina, G. Ragni, A. Bollati, R. Cozzi, M. Licini, C. Poiesi, S. Turazzi, and C. Bonfanti.\n\nMetabolism, Vol. 46, N. 4, p.425-430, 1997.\n\n96) Hexarelin, a novel GHRP-6 analog, stimulates growth hormone (GH) release in a GH-secreting rat cell line (GH1) insesitive to GH-releasing hormone.\n\nA. Giustina, C. Bonfanti, M. Licini, G. Ragni, B. Stefana.\n\nRegulatory Peptides Vol 70, p. 49-54, 1999.\n\n97) Haemodynamic effects of intravenous growth hormone in congestive heart failure.\n\nM. Volterrani, P. Desenzani, R. Lorusso, A. D’Aloia, F. Manelli, A. Giustina.\n\nThe Lancet. Vol. 349, N. 9058, p.1067-1068, 1997.\n\n98) Gowth hormone in end-stage heart failure.\n\nA. Giustina, M. Volterrani, P. Desenzani.\n\nThe Lancet.Vol. 349, N. 9068, p.1843, 1997.\n\n99) Maturation of the Regulation of Growth Hormone Secretion in Young Males with Hypogonadotropic Hypogonadism Pharmacologically Exposed to Progressive Increments in Serum Testosterone.\n\nA. Giustina, T. Scalvini, C. Tassi, P. Desenzani, C. Poiesi, W.B.Wehrenberg, A.D. Rogol, and J.D. Veldhuis.\n\nJournal of Clinical Endocrinology and Metabolism. Vol. 82, n 4, p 1210-1219. 1997.\n\n100) Effects of Food Deprivation on the GH Axis: Immunocytochemical and molecular Analysis.\n\nR. S. Brogan, S. K. Fife, L. K. Conley, A. Giustina, W. B. Wehrenberg.\n\nNeuroendocrinology, 65: 129-135, 1997.\n\n101) Modulation by Galanin of Growth Hormone and Gonadotropin Secretion from Perifused Petuitary and Median Eminence of Prepubertal Male Calves.\n\nM. Baratta, R. Saleri, C. Mascadri, D. H. Coy, A. Negro-Vilar, C. Tamanini, A. Giustina.\n\nNeuroendocrinology, 66: 271-277, 1997.\n\n102) Physiological Role of the Opioid-Cholinergic Interaction in Growth Hormone Neuroregulation: Effect of Sex and Food Intake.\n\nL. De Marinis, A. Mancini, D. Valle, C. Fiumara, G. Conte, A. Bianchi, M. Perrelli, R. Gentilella, A. Giustina.\n\nMetabolism, Vol. 46, N. 7, pp. 740-744, 1997.\n\n103) Effects of tamoxifen on GH and IGF-I levels in Acromegaly.\n\nR. Cozzi, R. Attanasio G. Oppizzi, P. Orlandi, A. Giustina, S. Lodrini, N. Da Re, and D. Dallabonzana.\n\nJournal of Endocrinological Investigation. 20: 445-451, 1997.\n\n1998\n\n104) Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats.\n\nL. K. Conley, R. C. Gaillard, A. Giustina, R. S. Borgan, W. B. Wehrenberg.\n\nJournal of Endocrinology, 158, 367-375, 1998.\n\n105) Long-Term Treatment with the Dual Antithromboxane Agent Picotamide Decreases Microalbuminuria in Normotensive Type 2 Diabetic Patients.\n\nA. Giustina, P. Perini, P. Desenzani, S. Bossoni, P. Ianniello, M. Milani, G. Davì, G. Romanelli.\n\nDiabetes, Vol. 47, N 3, p.423-430. 1998.\n\n106) Growth, Insulin-Like Growth Factor I (IGF-I), and IGF-Binding Proteins 1 and 3 in Children with Severe Liver Disease before and after Liver Transplantation: A Longitudinal and Cross-Sectional Study.\n\nF. Buzi, A. M. Bontempelli, D. Alberti, J. Jones, A. Pilotta, A. M. Lombardi, A. Giustina, M. A. Preece.\n\nPediatric Research, Vol. 43, N. 4, p. 478-483. 1998.\n\n107) Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human.\n\nA. Giustina, J. Veldhuis.\n\nEndocrine Reviews 19(6):717-797, 1998\n\n1999\n\n108) Short-Term glucocorticoid administration decreases both hypothalamic and pituitary galanin synthesis in adult male rat.\n\nR.S. Brogan, L.K. Coney, W.B. Wehrenberg, G. Beretta, and A. Giustina.\n\nMetabolism, Vol. 48, N 6, p 792-796. 1999.\n\n109) Effects of galanin infusion on GH secretion and GHRH-induced GH release in prepubertal male lambs.\n\nR. Saleri, M. Baratta, R. Renaville, D. Portetelle, D.H. Coy, A. Giustina, C. Tamanini.\n\nSmall Ruminant Research, 33 , 231-237. 1999.\n\n110) Cardiovascular effects of a single slow release Lanreotide injection in patients with acromegaly and left ventricular hypertrophy.\n\nF. Manelli, P. Desenzani, E. Boni, G. Bugari, F. Negrini, G. Romanelli, V. Grassi, and A. Giustina.\n\nPituitary; 2:205-210. 1999.\n\n111) Dehydropiandrosterone sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I.\n\nS.B. Solerte, M. Fioravanti, G. Vignati, A. Giustina, L. Cravello, and E. Ferrari.\n\nThe Journal of Clinical Endocrinology e Metabolism, Vol 84, N 9, 3260-3267. 1999.\n\n112) Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure.\n\nA. Giustina, M. Volterrani, F. Manelli, P. Desenzani, C. Poiesi, R. Lorusso, and A. Giordano.\n\nAmerican Heart Journal, Vol 137, N 6, p 1035-1043, 1999.\n\n2000\n\n113) Growth Hormone (GH) responses to GH-releasing hormone alone or combined with Arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.\n\nM. Terzolo, S. Bossoni, A. Alì, M. Doga, G. Reimondo, G. Milani, P. Peretti, F. Manelli, A. Angeli, and A. Giustina.\n\nThe Journal of Clinical Endocrinology and Metabolism. Vol 85, N 3, p. 1310-1315. 2000.\n\n114) Effects of Galanin on Growth hormone and Prolactin Secretion in Anorexia Nervosa.\n\nL. De Marinis, A. Mancini, D. Valle, A. Bianchi, R. Gentilella, D. Milardi, C. Mascadri, and A. Giustina.\n\nMetabolism. Vol. 49, N 2, p. 155-159. 2000.\n\n115) Exercise-induced microalbumunuria in patients with active acromegaly. Acute,effects of slow-release Lanreotide,a long-acting Somatostating analog.\n\nF. Manelli, S. Bossoni, A. Burattin, M. Doga, S.B. Solerte, G. Romanelli, and A. Giustina.\n\nMetabolism, Vol.49, N 5. p. 634-639. 2000.\n\n116) Acute and chronic galanin administration decreases hypothalamic galanin synthesis in both male and female, adult rats. Evidence for a long-loop galanin autofeedback.\n\nA. Giustina, R. Brogan, L. Conley, D. Godi, F. Manelli, and W.B. Wehrenberg.\n\nMetabolism, Vol.49, N 6, p. 778-783. 2000.\n\n117) Glucocorticoid-induced Osteoporosis.\n\nF. Manelli, and A. Giustina.\n\nTrends in Endocrinology and Metabolism. TEM Vol 11, N 3, p 79-85. 2000.\n\n118) CONSENSUS. Criteria for Cure of Acromegaly: A Consensus Statement.\n\nA. Giustina, A. Barkan, F.F. Casanueva, F. Cavagnini, L. Frohman, K. Ho, J. Veldhuis, J. Wass, K. Von Werder, and S. Melmed.\n\nThe Journal of Clinical Endocrinology and Metabolism. Vol 85, N 2, p. 526-529. 2000.\n\n119) Strategies for appraising suspected growth hormone, deficiency in the adult.\n\nJ. Veldhuis, A. Giustina.\n\nThe Endocrinologist . Vol.10: p.34-50. 2000.\n\n120) The Effects of a Continuos Infusion of Exsarelin on Pulsatile Growth Hormone Release, Growth Asix and Galanin Gene Expression and on the Response of the Growth Axis to Growth Hormone-Releasing Hormone.\n\nL.K. Conley, R.S. Brogan, A. Giustina, and W.B. Wehrenberg.\n\nPituitary . Vol 2, N 4, p. 253-260. 2000.\n\n121) Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: acute effects of continous octreotide infusion.\n\nG.Del Rio, A. Velardo, C. Mascadri, G. Zaltieri, G. Papi, R. Menozzi, A. Giustina.\n\nEuropean Journal of Endocrinology. 142:179-186, 2000\n\n122) Role of food intake in the modulation of Hexarelin-induced growth hormone release in normal human subjects.\n\nL. De Marinis, A. Mancini, D. Valle, D. Izzi, A. Bianchi, R. Gentilella, A. Giampietro, P. Desenzani, A. Giustina.\n\nHormone and Metabolic Research. vol. 32, p. 152-156. 2000.\n\n123) Role of Growth Hormone in Chronic Heart Failure.\n\n(Therapeutic Implications)\n\nM. Volterrani, F. Manelli, M. Cicoira, R. Lorusso and A. Giustina\n\nDrugs 2000. 60:711-719, 2000.\n\n2001\n\n124) Somatostatin analogs selective for subtype 2 and 5 of the somatostatin receptor suppress with different patterns growth hormone (GH) secretion in human GH-secreting adenoma cells cultured in vitro.\n\nG. Tulipano, C. Bonfanti, G. Milani, B. Billeci, A. Bollati, R. Cozzi, G. Maira, W.A. Marphy, C. Poiesi, S. Turazzi, A. Giustina.\n\nNeuroendocrinology. 73: p. 344-351. 2001.\n\n125) Glucocorticoid-Induced Osteoporosis: summary of a workshop.\n\nE. Canalis, A. Giustina.\n\nThe Journal of Clinical Endocrinoloy and Metabolism. Vol. 86, p 5681-5685, 2001.\n\n126) IGF-1, IGFBP-2 and -3 but not GH concentrations are different in normal and poor growing piglets.\n\nR. Saleri, M. Baratta, G.L. Mainardi, R. Renaville, A. Giustina, F. Quintavalla, C. Tamanini.\n\nReproduction Nutrition Development vol. 41, (2) p. 163-172. 2001.\n\n127) Acquired growth hormone resistance in patients with chronic heart failure: implication for therapy with growth hormone.\n\nS.D. Anker, M. Volterrani, C.D. Pflaum, C.J. Strasburger, K.J. Osterziel, W. Doehner, M.B. Ran. ke, P.A. Poole-Wilson, A. Giustina, R. Dietz, A.J.S. Coats.\n\nJournal of the American College of Cardiology. Vol 38, p. 443-452, 2001.\n\n128) Primary Lymphoma of the pituitary. an emerging clinical entity.\n\nA. Giustina, M. Gola, M. Doga, and E. Agabiti Rosei.\n\nThe Journal of Clinical Endocrinology and Metabolism. 86 (10), p. 4567-4575.2001.\n\n2002\n\n129) Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis.\n\nM. Doga, S. Bonadonna, A. Burattin, R. Carpinteri, F. Manelli, A. Giustina.\n\nFront Horm Res. Vol 30, p. 150-164. 2002.\n\n130) Growth hormone in glucocorticoid induced osteoporosis.\n\nF. Manelli, S. Bonadonna, A. Burattin, S. Bossoni, E. Agabiti Rosei, A. Giustina.\n\nFront Horm Res. Vol 30, p. 174-183. 2002.\n\n131) Long-term effects of lanreotide LAR on tumor shrinkage and GH hypersecretion in patients with previously untreated acromegaly.\n\nG. Amato, G. Maziotti, M. Rotondi, S. Iorio, M. Doga, F. Sorvillo, G. Manganella, F. Di Salle, A. Giustina, C. Carella.\n\nClinical Endocrinology Vol 56, p.65-71, 2002.\n\n132) Leptin regulates GH gene expression and secretion and nitric oxide production in pig pituitary cells.\n\nM. Baratta, R. Saleri, G.L. Mainardi, D. Valle, A. Giustina C. Tamanni.\n\nEndocrinology. Vol. 143, p.551-557, 2002.\n\n133) Preoperative Growth Hormone response to Thyrotropin-Releasing Hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.\n\nL. De Marinis, A. Mancini, A. Bianchi, A. Gentilella, D. Valle, A. Giampietro, P. Zuppi, C. Anile, G. Maira, A. Giustina.\n\nMetabolism, Vol. 51 (5) p. 616-621. 2002.\n\n134) A. retrospective hormonal and immunohistochemical evaluation of 47 acromegalic patients: prognostic value of preoperative plasma prolactin.\n\nL. De Marinis, P. Zuppi, D. Valle, A. Mancini, A. Bianchi, L. Lauriola, P. Pasquini, C. Anile, G. Maira, A. Giustina.\n\nHormone and Metabolic Research. Vol. 34, p.137- 143, 2002.\n\n135) Characterization of new selective somatostatin receptor subtype-2 ( sst2 ) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment.\n\nG. Tulipano, D. Soldi, M. Bagnasco, M.D. Culler, J.E. Taylor, D. Cocchi, and A. Giustina.\n\nEndocrinology 143 (4), p.1218-1224, 2002.\n\n136) CONSENSUS. Guidelines for acromegaly management.\n\nS. Melmed, F.F. Casanueva, F. Cavagnini, P. Chanson, L. Frohman, A. Grossman, K. Ho, D. Kleinberg, S. Lamberts, E. Laws, G. Lombardi, M.L. Vance, K. Von Werder, J. Wass and A. Giustina, for the Acromegaly Treatment Consensus Workshop Participants.\n\nThe Journal of Clinical Endocrinology and Metabolism. Vol 87, N 9, p. 4054-4058. 2002.\n\n137) Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.\n\nM.A. Ambrosio, P. Franceschetti, M. Bondanelli, M. Doga, P. Maffei, R. Baldelli, G. Tamburrano, N. Sicolo, A. Giustina, and E. degli Uberti.\n\nMetabolism vol. 51, n 3, p 387-393, 2002.\n\n138) Growth hormone secretagogue ( GHS ) analogue, hexarelin stimulated GH from peripheral lymphocytes.\n\nL. Poppi, V.D. Dixit, M. Baratta, A. Giustina, C. Tamanni, N. Parvizi.\n\nExperimental and Clinical Endocrinology & Diabetes.Vol 10, p. 343-347, 2002.\n\n139) Consensus document on substitution therapy with testosterone in hypoandrogenic elderly men.\n\nG. Valenti, S. Bossoni, A. Giustina, D. Maugeri, M. Motta, G. B. Vigna, R. Fellin, F. Corica, A. Corsonello, G. Paolisso, M. Barbagallo, L. Dominguez, L. Denti, GP.Ceda, E. Ferrari, B. Pontiggia, F. Strollo.\n\nAging clinical and experimental research. Vol. 14, p. 439-464. 2002.\n\n2003\n\n140) Preliminary observation on the effect of acute infusion of growth hormone on coronary vasculature and on myocardial function and energetics of an isolated and blood-perfused heart.\n\nR. Lorusso, E. Pasini, A. Cargnoni, C. Cecconi, M. Volterrani, A. Burattin D. Valle, R. Ferrari and A. Giustina.\n\nJournal of Endocrinological Investigation . Vol. 26, N 1, p.RC1-RC4. 2003.\n\n141) Acromegaly consensus the next step\n\nA. Giustina, S. Melmed.\n\nThe Journal of Clinical Endocrinology and Metabolism. Vol 88, N 4, p.1913-1914. 2003\n\n142) Developementof meningioma in a patient with acromegaly during octreotide treatment. Are there any causal relationships ?\n\nE. De Menis, G. Tulipano, S. Villa, D. Billeci, C. Bonfanti, P. Pollara, P.Pauletto, A. Giustina.\n\nJournal Endocrinolological Investigation. Vol. 26, p.359-363, 2003.\n\n143) Trasformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma causing high levels of insulin-like growth factor 1 (IGF-1).\n\nA. Tucci, S. Bonadonna, C. Cattaneo, M. Ungari, A. Giustina, and G. Rossi.\n\nLeukemia & Lymphoma. Vol 44 n° 3 p 543-545. 2003.\n\n144) Diagnosis and treatment of acromegaly complications.\n\nA. Giustina F.F. Casanueva, F. Cavagnini, P. Chanson, D. Clemmons, L.A. Frohman, R. Gaillard, K. Ho, P.Jaquet, D.L. Kleinberg, S.W. Lamberts, G. Lombardi, M. Sheppard, C.J Strasburger, M.L. Vance, J. Wass, S. Melmed.\n\nJournal Endocrinological Investigation, Vol 26 N 12. p.1242-1247. 2003\n\n145) Influence of type 2 diabetes on funtional and structural properties of coronary artery bypass conduits.\n\nR. Lorusso, S. Pentiricci, R. Raddino, T.M. Scarabelli, V. Villanucci, A. Burattin, G. Romanelli, S. Casari, R. Scelsi, A. Giustina.\n\nDiabetes Vol 52 p 2814-2820. 2003.\n\n146) Diagnosis and complications of Cushing’s syndrome: a consensus statement.\n\nG. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro.\n\nJournal of Clinical Endocrinology and Metabolism, Vol 88 N 12. p.5593-5602. 2003\n\n2004\n\n147) Perspectives on glucocorticoid-induced osteoporosis.\n\nE. Canalis, J.P Bilezikian, A. Angeli A. Giustina.\n\nBone. Vol. 34 (8), p 593-8. 2004.\n\n148) Leptin stimulates growth hormone secretion via a direct pituitary effect combined with a Decreases somatostatin tone in a median eminence-pituitary perifusion study.\n\nR. Saleri, A. Giustina, C. Tamanini, D. Valle, A. Burattin, W.B.Wehrenberg, M. Baratta.\n\nNeuroendocrinology.Vol. 79 (4) p. 221-228. 2004.\n\n149) Effects of the selective estrogen receptor modulator ( SERM) LY117018 on growth hormone (GH) secretion: in vitro study.\n\nG. Tulipano, C. Bonfanti, C. Poiesi, A. Burattin, S. Turazzi, G. Barone, R. Cozzi, A. Bollati, D. Valle, A. Giustina.\n\nMetabolism. Vol.53, N 5, p. 563-570. 2004.\n\n150) Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous smoll resistence arteries.\n\nD. Rizzoni, E. Porteri, , A. Giustina, C. De Ciuceis, I. Sleiman, G.E. Boari, C. Castellano, M.L.Muiesan, S. Bonadonna, A. Burattin, B. Cerudelli, E. Agabiti-Rosei.\n\nHypertension. Vol. 43, N 3, p. 561-565. 2004\n\n151) Primary pituitary lymphpoma: a clinical-patological update.\n\nM. Gola, M. Doga, S. Bonadonna, A. Giustina\n\nThe Endocrinologist. 14(5):288-292, 2004\n\n152) Glucocorticocoids and bone: cellular, metabolic and endocrine effects.\n\nM. Doga, S. Bonadonna, A. Giustina.\n\nHormones. Vol 3, N° 3, p.184-190. 2004\n\n153) High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical tretment.\n\nG. Amato, G. Mazziotti, F. Sorvillo, M. Piscopo, E. Lali, B. Biondi, S. Iorio, A. Molinari, A. Giustina,, C. Carella.\n\nBone, Vol. 35, n 3, p. 785-791. 2004.\n\n154) Cushing’s syndrome and bone.\n\nMancini T, Doga M, Mazziotti G, Giustina A.\n\nPituitary. 2004;7(4):249-52.\n\n2005\n\n155) Chronic glucocorticoid treatment alter spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects.\n\nS. Bonadonna, A. Burattin, M. Nuzzo, G. Bulgari, E. Agabiti-Rosei, D. Valle, N. Iori, G.P. Bilezikian, J.D. Veldhuis and A. Giustina.\n\nEuropean Journal of Endocrinology. 152: N° 2 p. 199-205, 2005\n\n156) Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receving long-term inhaled corticosteroid treatment.\n\nM. Malerba, S. Bossoni, A. Radaeli, E. Mori, S. Bonadonna, A. Giustina and C. Tantucci.\n\nChest Vol. 27 p. 515-521. 2005.\n\n157) Current guidelines for adult GH replacement.\n\nM. Doga, S. Bonadonna , M. Gola, S.B. Solerte, G. Amato, C. Carella and, A. Giustina.\n\nReviews in Endocrine & Metabolic Disorders. Vol 6, p 63-70. 2005\n\n158) Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer’s disease: recovering effect with insulin and DHEA sulfate.\n\nSolerte SB, Ferrari E, Cuzzoni G, Locatelli E, Giustina A, Zamboni M, Schifino N, Rondanelli M, Gazzaruso C, Fioravanti M.\n\nDementia Geriatric Cognitive Disorders. 19(1): p. 1-10. 2005.\n\n159) The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat.\n\nTulipano G, Rossi E, Culler MD, Taylor JE, Bonadonna S, Locatelli V, Cocchi D, Giustina A.\n\nRegulatory Peptides 2005 ;125(1-3):85-92.\n\n160) Clinical review: Growth hormone and cardiovascular risk factors.\n\nGola M, Bonadonna S, Doga M, Giustina A.\n\nJournal of Clinical Endocrinology and Metabolism. 2005 ;90(3):1864-70.\n\n161) Ghrelin regulates proliferation and differentiation of osteoblastic cells.\n\nMaccarinelli G, Sibilia V, Torsello A, Raimondo F, Pitto M, Giustina A, Netti C, Cocchi D.\n\nJournal of Endocrinology 2005 ;184(1):249-56.\n\n162) Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.\n\nMazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, Iorio S, Giustina A, Amato G, Carella C.\n\nJournal of Bone and Mineral Research 2005 ;20(3):480-6.\n\n163) Primary empty sella.\n\nDe Marinis L, Bonadonna S, Bianchi A, Maira G, Giustina A.\n\nJournal of Clinical Endocrinology and Metabolism. 2005 ;90(9):5471-7.\n\n164) Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.\n\nBondanelli M, Bonadonna S, Ambrosio MR, Doga M, Gola M, Onofri A, Zatelli MC, Giustina A, degli Uberti EC.\n\nMetabolism. 2005 ;54(9):1174-80.\n\n165) Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women.\n\nBonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, Giustina A.\n\nJ Bone Miner Res. 2005 ;20(10):1837-44.\n\n166) Cardiovascular risk in aging and obesity: is there a role for GH.\n\nGola M, Bonadonna S, Doga M, Mazziotti G, Giustina A.\n\nJ Endocrinol Invest. 2005 ;28(8):759-67.\n\n167) Consensus statement: medical management of acromegaly.\n\nMelmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A.\n\nEur J Endocrinol. 2005 ;153(6):737-40.\n\n2006\n\n168) Bone ultrasonometric features and growth hormone secretion in asthmatic patients during chronic inhaled corticosteroid therapy.\n\nMalerba M, Bossoni S, Radaeli A, Mori E, Romanelli G, Tantucci C, Giustina A, Grassi V.\n\nBone. 2006 Jan;38(1):119-2\n\n169) Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients.\n\nGazzaruso C, Pujia A, Solerte SB, Amici ED, Emanuele E, Falcone C, Geroldi D, Giustina A, Garzaniti A.\n\nInt J Impot Res. 2006 May-Jun;18(3):311-5.\n\n170) Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with type 2 diabetes mellitus.\n\nGazzaruso C, Solerte SB, De Amici E, Mancini M, Pujia A, Fratino P, Giustina A, Garzaniti A.\n\nAm J Cardiol. 2006 Jan 15;97(2):236-9.\n\n171) Resistance to somatostatin analogs in acromegaly: an evolving concept?\n\nGola M, Bonadonna S, Mazziotti G, Amato G, Giustina A.\n\nJ Endocrinol Invest. 2006 Jan;29(1):86-93.\n\n172) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study.\n\nAngeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, Giorgino R, Moro L, Giustina A.\n\nBone. 2006 Aug;39(2):253-9.\n\n173) Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy.\n\nMazziotti G, Bianchi A, Bonadonna S, Nuzzo M, Cimino V, Fusco A, De Marinis L, Giustina A.\n\nJ Bone Miner Res. 2006 Apr;21(4):520-8.\n\n174) Glucocorticoid-induced osteoporosis: an update.\n\nMazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A.\n\nTrends Endocrinol Metab. 2006 May-Jun;17(4):144-9\n\n175) Development of Graves’ hyperthyroidism during the early phase of pregnancy in a patient with pre-existing and long-standing Hashimoto’s hypothyroidism.\n\nGola M, Doga M, Mazziotti G, Bonadonna S, Giustina A.\n\nJ Endocrinol Invest. 2006 Mar;29(3):288-90.\n\n176) Active acromegaly enhances spontaneous parathyroid hormone pulsatility.\n\nMazziotti G, Cimino V, De Menis E, Bonadonna S, Bugari G, De Marinis L, Veldhuis JD, Giustina A.\n\nMetabolism. 2006 Jun;55(6):736-40.\n\n177) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.\n\nCasanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A.\n\nClin Endocrinol (Oxf). 2006 Aug;65(2):265-73.\n\n178) Thyroid autoimmunity and spontaneous cervical artery dissection.\n\nPezzini A, Del Zotto E, Mazziotti G, Ruggeri G, Franco F, Giossi A, Giustina A, Padovani A.\n\nStroke. 2006 Sep;37(9):2375-7.\n\n179) Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.\n\nGola M, Doga M, Bonadonna S, Mazziotti G, Vescovi PP, Giustina A.\n\nPituitary. 2006; 9: 221-9\n\n180) Consensus Document on substitution therapy with DHEA in the elderly.\n\nValenti G, Denti L, Sacco M, Ceresini G, Bossoni S, Giustina A, Maugeri D, Vigna GB, Fellin R, Paolisso G, Barbagallo M, Maggio M, Strollo F, Bollanti L, Romanelli F, Latini M.\n\nAging Clin Exp Res. 2006 Aug;18(4):277-300.\n\n181) Growth hormone deficiency in the adult.\n\nDoga M, Bonadonna S, Gola M, Mazziotti G, Giustina A.\n\nPituitary. 2006;9(4):305-11\n\n182) Development of acromegaly in a patient with anorexia nervosa: Pathogenetic and diagnostic implications.\n\nde Menis E, Gola M, Giustina A.\n\nJournal of Endocrinological Investigation 2006 Oct;29(9):821-5.\n\n2007\n\n183) Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG NO-aspirin and vein grafts in type-2 diabetes mellitus.\n\nLorusso R, De Cicco G, Beghi C, Gherli T, Poli E, Corradi D, Maestri R, Bonadonna S, Mancini T, Giustina A.\n\nInt J Cardiol. 2007; 118: 164-9\n\n184. Mechanisms of anabolic therapies for osteoporosis.\n\nCanalis E, Giustina A, Bilezikian JP.\n\nN Engl J Med. 2007 Aug 30;357(9):905-16.\n\n185. Does growth hormone replacement therapy improve cardiac function?\n\nGiustina A.\n\nNat Clin Pract Endocrinol Metab. 2007 Sep;3(9):614-5.\n\n186. Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125.\n\nTulipano G, Taylor JE, Halem HA, Datta R, Dong JZ, Culler MD, Bianchi I, Cocchi D, Giustina A.\n\nPituitary. 2007;10(3):267-74.\n\n187. Glucocorticoid-induced osteoporosis: pathophysiology and therapy.\n\nCanalis E, Mazziotti G, Giustina A, Bilezikian JP.\n\nOsteoporos Int. 2007 Oct;18(10):1319-28\n\n188. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.\n\nDe Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A.\n\nPituitary. 2007;10(3):227-32.\n\n189. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.\n\nMaison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P.\n\nJ Clin Endocrinol Metab. 2007 May;92(5):1743-7.\n\n190. Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG.\n\nLorusso R, De Cicco G, Beghi C, Gherli T, Poli E, Corradi D, Maestri R, Bonadonna S, Mancini T, Giustina A.\n\nInt J Cardiol. 2007 May 31;118(2):164-9.\n\n191. Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects.\n\nMazziotti G, Giustina A, Canalis E, Bilezikian JP.\n\nArq Bras Endocrinol Metabol. 2007 Nov;51(8):1404-12.\n\n192. Pegvisomant in acromegaly: why, when, how.\n\nColao A, Arnaldi G, Beck-Peccoz P, Cannavò S, Cozzi R, degli Uberti E, De Marinis L, De Menis E, Ferone D, Gasco V, Giustina A, Grottoli S, Lombardi G, Maffei P, Martino E, Minuto F, Pivonello R, Ghigo E.\n\nJ Endocrinol Invest. 2007 Sep;30(8):693-9.\n\n2008\n\n193. The management of the patient with acromegaly and headache: a still open clinical challenge.\n\nGiustina A, Gola M, Colao A, De Marinis L, Losa M, Sicolo N, Ghigo E.\n\nJ Endocrinol Invest. 2008 Oct;31(10):919-24.\n\n194. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.\n\nGiustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S; Pituitary Society; European Neuroendocrine Association.\n\nJ Endocrinol Invest. 2008 Sep;31(9):820-38.\n\n195. Prevention and treatment of glucocorticoid-induced osteoporosis.\n\nDoga M, Mazziotti G, Bonadonna S, Patelli I, Bilezikian JP, Canalis E, Giustina A.\n\nJ Endocrinol Invest. 2008 Jul;31(7 Suppl):53-8.\n\n196. Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.\n\nGiustina A, Mancini T, Boscani PF, de Menis E, degli Uberti E, Ghigo E, Martino E, Minuto F, Colao A; COM.E.T.A. (COMorbidities Evaluation and Treatment inAcromegaly) Italian Study Group.\n\nJ Endocrinol Invest. 2008 Aug;31(8):731-8.\n\n197. Prevalence of vertebral fractures in men with acromegaly.\n\nMazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A, Pontecorvi A, De Marinis L, Giustina A.\n\nJ Clin Endocrinol Metab. 2008 Dec;93(12):4649-55\n\n198. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease.\n\nDavi’ MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, Francia G.\n\nEur J Endocrinol. 2008 Nov;159(5):533-40\n\n199. Biochemical evaluation of patients with active acromegaly and type 2 diabetes mellitus: efficacy and safety of the galanin test.\n\nMazziotti G, Bonadonna S, Doga M, Patelli I, Gazzaruso C, Solerte SB, De Menis E, Giustina A.\n\nNeuroendocrinology. 2008;88(4):299-304.\n\n200. Nutritional supplements with oral amino acid mixtures increases whole-body lean mass and insulin sensitivity in elderly subjects with sarcopenia.\n\nSolerte SB, Gazzaruso C, Bonacasa R, Rondanelli M, Zamboni M, Basso C, Locatelli E, Schifino N, Giustina A, Fioravanti M.\n\nAm J Cardiol. 2008 ;101(11A):69E-77E\n\n201. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors.\n\nGazzaruso C, Solerte SB, Pujia A, Coppola A, Vezzoli M, Salvucci F, Valenti C, Giustina A, Garzaniti A.\n\nJ Am Coll Cardiol. 2008 May 27;51(21):2040-4.\n\n202. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas.\n\nFusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Veltri F, Angelini F, Lauriola L, Vellone V, Doglietto F, Ambrosio MR, Maira G, Giustina A, degli Uberti EC, Pontecorvi A, De Marinis L.\n\nJ Clin Endocrinol Metab. 2008 Jul;93(7):2746-50.\n\n203. Growth hormone, insulin-like growth factors, and the skeleton.\n\nGiustina A, Mazziotti G, Canalis E.\n\nEndocr Rev. 2008 Aug;29(5):535-59.\n\n204. Pituitary testing: a reappraisal.\n\nGiustina A.\n\nPituitary. 2008;11(2):113-4.\n\n205. Hyperprolactinemia and prolactinomas.\n\nMancini T, Casanueva FF, Giustina A.\n\nEndocrinol Metab Clin North Am. 2008 Mar;37(1):67-99, viii.\n\n206. Relationship between instrumental activities of daily living and blood glucose control in elderly subjects with type 2 diabetes.\n\nBossoni S, Mazziotti G, Gazzaruso C, Martinelli D, Orini S, Solerte SB, Romanelli G, Giustina A.\n\nAge Ageing. 2008 Mar;37(2):222-5.\n\n207. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.\n\nDe Marinis L, Bianchi A, Mazziotti G, Mettimano M, Milardi D, Fusco A, Cimino V, Maira G, Pontecorvi A, Giustina A.\n\nPituitary. 2008;11(1):13-20.\n\n208. Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency.\n\nMazziotti G, Bianchi A, Cimino V, Bonadonna S, Martini P, Fusco A, De Marinis L, Giustina A.\n\nPituitary. 2008;11(1):55-61.\n\n2009\n\n209. Pituitary tumours: inflammatory and granulomatous expansive lesions of the pituitary.\n\nCarpinteri R, Patelli I, Casanueva FF, Giustina A.\n\nBest Pract Res Clin Endocrinol Metab. 2009 Oct;23(5): 639-650\n\n210. Pituitary gland: Medical therapy for acromegaly: can we predict response?\n\nGiustina A, Porcelli T.\n\nNat Rev Endocrinol. 2009 Aug;5:425-7.\n\n211. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.\n\nMancini T, Mazziotti G, Doga M, Carpinteri R, Simetovic N, Vescovi PP, Giustina A.\n\nBone 2009; 45(4):784-8\n\n212. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.\n\nGiustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, de Marinis L, Degli Uberti E, Bogazzi F, Mazziotti G, Minuto F, Montini M, Ghigo E.\n\nEur J Endocrinol. 2009 Aug;161:331-8.\n\n213. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.\n\nBianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L.\n\nJ Clin Endocrinol Metab. 2009 Jun;94(6):2015-22.\n\n214. Treatment with metformin is protective against limitations in instrumental activities of daily living in older subjects with type 2 diabetes mellitus.\n\nMazziotti G, Bossoni S, Orini S, Salimbeni P, Gazzaruso C, Solerte BS, Vescovi P, Romanelli G, Giustina A.\n\nJ Am Geriatr Soc. 2009 Mar;57(3):562-4.\n\n215. Guidelines for acromegaly management: an update.\n\nMelmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A; Acromegaly Consensus Group.\n\nJ Clin Endocrinol Metab. 2009 May;94(5):1509-17.\n\n216. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies.\n\nMazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A.\n\nJ Clin Endocrinol Metab. 2009 May;94(5):1500-8.\n\n217. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly.\n\nBianchi A, Mazziotti G, Tilaro L, Cimino V, Veltri F, Gaetani E, Pecorini G, Pontecorvi A, Giustina A, De Marinis L.\n\nPituitary. 2009;12(3):196-9.\n\n2010\n\n218. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.\n\nMazziotti G, Giustina A.\n\nPituitary 2010; 13: 60-67\n\n219. Glucocorticoid-induced osteoporosis and parathyroid hormone.\n\nCarpinteri R, Porcelli T, Mejia C, Patelli I, Bilezikian JP, Canalis E, Angeli A, Giustina A, Mazziotti G.\n\nJ Endocrinol Invest. 2010;33(7 Suppl):16-21.\n\n220 Treatment of Cushing disease: overview and recent findings.\n\nMancini T, Porcelli T, Giustina A.\n\nTher Clin Risk Manag. 2010 Oct 21;6:505-16.\n\n221. Drug-induced osteoporosis: mechanisms and clinical implications.\n\nMazziotti G, Canalis E, Giustina A.\n\nAm J Med. 2010 Oct;123(10):877-84.\n\n222. A consensus on criteria for cure of acromegaly.\n\nGiustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S; Acromegaly Consensus Group.\n\nJ Clin Endocrinol Metab. 2010 Jul;95(7):3141-8.\n\n223. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency.\n\nMazziotti G, Porcelli T, Bianchi A, Cimino V, Patelli I, Mejia C, Fusco A, Giampietro A, De Marinis L, Giustina A.\n\nEur J Endocrinol. 2010 Jul;163(1):15-20\n\n224. Primary empty sella: Why and when to investigate hypothalamic-pituitary function.\n\nGiustina A, Aimaretti G, Bondanelli M, Buzi F, Cannavò S, Cirillo S, Colao A, De Marinis L, Ferone D, Gasperi M, Grottoli S, Porcelli T, Ghigo E, degli Uberti E.\n\nJ Endocrinol Invest. 2010 May;33(5):343-6\n\n225. Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density.\n\nMazziotti G, Porcelli T, Patelli I, Vescovi PP, Giustina A.\n\nBone. 2010 Mar;46(3):747-51\n\n2011\n\n226. Diabetes in Cushing syndrome: basic and clinical aspects.\n\nMazziotti G, Gazzaruso C, Giustina A.\n\nTrends Endocrinol Metab. 2011 Dec;22(12):499-506.\n\n227. Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes.\n\nGazzaruso C, Coppola A, Montalcini T, Valenti C, Garzaniti A, Pelissero G, Salvucci F, Gallotti P, Pujia A, Falcone C, Solerte SB, Giustina A.\n\nEndocrine. 2011 Oct;40(2):273-9.\n\n228. Influence of diabetes mellitus on vertebral fractures in men with acromegaly.\n\nMazziotti G, Gola M, Bianchi A, Porcelli T, Giampietro A, Cimino V, Doga M, Gazzaruso C, De Marinis L, Giustina A.\n\nEndocrine. 2011 Aug;40(1):102-8.\n\n229. Vertebral fractures in males with prolactinoma.\n\nMazziotti G, Porcelli T, Mormando M, De Menis E, Bianchi A, Mejia C, Mancini T, De Marinis L, Giustina A.\n\nEndocrine. 2011 Jun;39(3):288-93.\n\n230. Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group.\n\nDe Menis E, Giustina A, Colao A, Degli Uberti E, Ghigo E, Minuto F, Bogazzi F, Drigo R, Cattaneo A, Aimaretti G; COM.E.T.A. Italian Study Group.\n\nJ Endocrinol Invest. 2011 Jan;34(1):60-4. Erratum in: J Endocrinol Invest. 2011 Feb;34(2):169.\n\n231. Erectile dysfunction and coronary artery disease in patients with diabetes.\n\nGazzaruso C, Coppola A, Giustina A.\n\nCurr Diabetes Rev. 2011 Mar;7(2):143-7.\n\n232. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas.\n\nMazziotti G, Mancini T, Mormando M, De Menis E, Bianchi A, Doga M, Porcelli T, Vescovi PP, De Marinis L, Giustina A.\n\nPituitary. 2011 Dec;14(4):299-306.\n\n233. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy.\n\nMazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannavò S, Colao A, Cozzi R, De Marinis L, degli Uberti E, Grottoli S, Minuto F, Montini M, Spinello M, Giustina A.\n\nEur J Endocrinol. 2011 Mar;164(3):341-7\n\n234. Current management practices for acromegaly: an international survey.\n\nGiustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, Melmed S.\n\nPituitary. 2011 Jun;14(2):125-33. doi: 10.1007/s11102-010-0269-9.\n\n2012\n\n235. Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure.\n\nMazziotti G, Baracca M, Doga M, Porcelli T, Vescovi PP, Giustina A.\n\nEur J Endocrinol. 2012 Dec;167(6):865-72.\n\n236. Growth hormone deficiency and cardiovascular risk: do we need additional markers?\n\nGola M, Giustina A.\n\nEndocrine. 2012 Oct;42(2):240-2.\n\n237. Keep an eye on nonfunctioning pituitary adenomas.\n\nGiustina A.\n\nClin Endocrinol (Oxf). 2012 Nov;77(5):656-7.\n\n238. Points of integration between the intracellular energy sensor AMP-activated protein kinase (AMPK) activity and the somatotroph axis function.\n\nTulipano G, Faggi L, Sibilia V, Giustina A.\n\nEndocrine. 2012 Oct;42(2):292-8.\n\n239. Meta-analysis on the effects of octreotide on tumor mass in acromegaly.\n\nGiustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S.\n\nPLoS One. 2012;7(5):e36411.\n\n240. Type 2 diabetes mellitus is associated with faster degeneration of bioprosthetic valve: results from a propensity score-matched Italian multicenter study.\n\nLorusso R, Gelsomino S, Lucà F, De Cicco G, Billè G, Carella R, Villa E, Troise G, Viganò M, Banfi C, Gazzaruso C, Gagliardotto P, Menicanti L, Formica F, Paolini G, Benussi S, Alfieri O, Pastore M, Ferrarese S, Mariscalco G, Di Credico G, Leva C, Russo C, Cannata A, Trevisan R, Livi U, Scrofani R, Antona C, Sala A, Gensini GF, Maessen J, Giustina A.\n\nCirculation. 2012 Jan 31;125(4):604-14.\n\n241. High prevalence of radiological vertebral fractures in HIV-infected males.\n\nTorti C, Mazziotti G, Soldini PA, Focà E, Maroldi R, Gotti D, Carosi G, Giustina A.\n\nEndocrine. 2012 Jun;41(3):512-7. doi: 10.1007/s12020-011-9586-7\n\n242. New understanding and treatments for osteoporosis.\n\nMazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A.\n\nEndocrine. 2012 Feb;41(1):58-69. doi: 10.1007/s12020-011-9570-2.\n\n243. Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus.\n\nGazzaruso C, Coppola A, Montalcini T, Baffero E, Garzaniti A, Pelissero G, Collaviti S, Grugnetti A, Gallotti P, Pujia A, Solerte SB, Giustina A.\n\nEndocrine. 2012 Feb;41(1):89-95.\n\n244. Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients.\n\nGazzaruso C, Coppola A, Montalcini T, Valenti C, Pelissero G, Solerte SB, Salvucci F, Gallotti P, Pujia A, Garzaniti A, Giustina A.\n\nIntern Emerg Med. 2012 Jun;7(3):257-66. doi: 10.1007/s11739-011-0527-5. Epub 2011 Feb 5.\n\n2013\n\n245. Octreotide for acromegaly treatment: a reappraisal.\n\nGiustina A, Karamouzis I, Patelli I, Mazziotti G.\n\nExpert Opin Pharmacother. 2013 Dec;14(17):2433-47.\n\n246. Commentary: Postsurgical monitoring of acromegaly.\n\nGiustina A, Mazziotti G, Fontanella M.\n\nNeurosurgery. 2013 Oct;73(4):E746-8.\n\n247. Fat utilization and arterial hypertension in overweight/obese subjects.\n\nFerro Y, Gazzaruso C, Coppola A, Romeo S, Migliaccio V, Giustina A, Pujia A, Montalcini T.\n\nJ Transl Med. 2013 Jul 2;11:159.\n\n248. Vertebral fractures in patients with acromegaly: a 3-year prospective study.\n\nMazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A, Giampietro A, De Marinis L, Giustina A.\n\nJ Clin Endocrinol Metab. 2013 Aug;98(8):3402-10\n\n249. Percutaneous transluminal angioplasty for critical limb ischemia in very elderly diabetic patients.\n\nGazzaruso C, Coppola A, Collaviti S, Saluzzo CM, Furlani F, Gallotti P, Clerissi J, Solerte BS, Giustina A.\n\nAging Clin Exp Res. 2013 May;25(2):225-8.\n\n250. Primary headache and silent myocardial ischemia in patients with coronary artery disease.\n\nFalcone C, Bozzini S, Gazzaruso C, Calcagnino M, Ghiotto N, Falcone R, Coppola A, Giustina A, Pelissero G.\n\nCardiology. 2013;125(3):133-8.\n\n251. Effect of different diabetes mellitus treatments on functional decline and death in elderly adults with diabetes mellitus.\n\nGazzaruso C, Coppola A, Luppi C, Giustina A, Solerte SB.\n\nJ Am Geriatr Soc. 2013 Apr;61(4):666-7\n\n252. Should we abandon statins in the prevention of bone fractures?\n\nEsposito K, Capuano A, Sportiello L, Giustina A, Giugliano D.\n\nEndocrine. 2013 Oct;44(2):326-33\n\n253. Transcutaneous oxygen tension as a potential predictor of cardiovascular events in type 2 diabetes: comparison with ankle-brachial index.\n\nGazzaruso C, Coppola A, Falcone C, Luppi C, Montalcini T, Baffero E, Gallotti P, Pujia A, Solerte SB, Pelissero G, Giustina A\n\nDiabetes Care 2013 June; 36: 1720-5\n\n254. Glucocorticoids and the regulation of growth hormone secretion.\n\nMazziotti G, Giustina A.\n\nNat Rev Endocrinol. 2013 May;9(5):265-76.\n\n255. Effects of AMPK activation and combined treatment with AMPK activators and somatostatin on hormone secretion and cell growth in cultured GH-secreting pituitary tumor cells.\n\nTulipano G, Faggi L, Losa M, Mortini P, Spinello M, Sibilia V, Pagani F, Cocchi D, Giustina A.\n\nMol Cell Endocrinol. 2013 Jan 30;365(2):197-206.\n\n256. Effects of recombinant follicle-stimulating hormone on bone turnover markers in infertile women undergoing in vitro fertilization procedure.\n\nOmodei U, Mazziotti G, Donarini G, Gola M, Guella V, Pagani F, Bugari G, Porcelli T, Giustina A.\n\nJ Clin Endocrinol Metab. 2013 Jan;98(1):330-6.\n\n257. A consensus on the diagnosis and treatment of acromegaly complications.\n\nMelmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A.\n\nPituitary. 2013 Sep;16(3):294-302.\n\n2014\n\n258. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline.\n\nGiustina A, Ambrosio MR, Beck Peccoz P, Bogazzi F, Cannavo’ S, De Marinis L, De Menis E, Grottoli S, Pivonello R.\n\nJ Endocrinol Invest. 2014 Oct;37(10):1017-30.\n\n259. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.\n\nGiustina A, Mazziotti G, Maffezzoni F, Amoroso V, Berruti A.\n\nExpert Opin Investig Drugs. 2014 Dec;23(12):1619-35.\n\n260. Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection.\n\nPorcelli T, Gotti D, Cristiano A, Maffezzoni F, Mazziotti G, Focà E, Castelli F, Giustina A, Quiros-Roldan E.\n\nOsteoporos Int. 2014 Sep;25(9):2263-9.\n\n261. Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs.\n\nMazziotti G, Maffezzoni F, Doga M, Hofbauer LC, Adler RA, Giustina A.\n\nBone. 2014 Oct;67:175-80.\n\n262. Molecular imaging in acromegaly: should clinicians look carefully at developments in the field?\n\nGiustina A, Mazziotti G, Giubbini R.\n\nNucl Med Commun. 2014 Sep;35(9):897-9.\n\n263. GH receptor isoforms and skeletal fragility in acromegaly.\n\nMormando M, Nasto LA, Bianchi A, Mazziotti G, Giampietro A, Pola E, Pontecorvi A, Giustina A, De Marinis L.\n\nEur J Endocrinol. 2014 Aug;171(2):237-45\n\n264. Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism.\n\nMazziotti G, Mormando M, Cristiano A, Bianchi A, Porcelli T, Giampietro A, Maffezzoni F, Serra V, De Marinis L, Giustina A.\n\nEur J Endocrinol. 2014 Jun;170(6):893-9\n\n265. Elevated intraocular pressure in patients with acromegaly.\n\nQuaranta L, Riva I, Mazziotti G, Porcelli T, Floriani I, Katsanos A, Giustina A, Konstas AG.\n\nGraefes Arch Clin Exp Ophthalmol. 2014 Jul;252(7):1133-9\n\n266. Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect.\n\nGiustina A, Mazziotti G.\n\nEndocrine. 2014 Nov;47(2):354-6\n\n267. Expert consensus document: A consensus on the medical treatment of acromegaly.\n\nGiustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S; Acromegaly Consensus Group.\n\nNat Rev Endocrinol. 2014 Apr;10(4):243-8.\n\n268. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications.\n\nKamenický P, Mazziotti G, Lombès M, Giustina A, Chanson P.\n\nEndocr Rev. 2014 Apr;35(2):234-81.\n\n269. Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?\n\nScillitani A, Mazziotti G, Di Somma C, Moretti S, Stigliano A, Pivonello R, Giustina A, Colao A; ABC Group.\n\nOsteoporos Int. 2014 Feb;25(2):441-6.\n\n270. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH–an update.\n\nGazzaruso C, Gola M, Karamouzis I, Giubbini R, Giustina A.\n\nJ Clin Endocrinol Metab. 2014 Jan;99(1):18-29.\n\n271. Interplay between the intracellular energy sensor AMP-activated protein kinase (AMPK) and the estrogen receptor activities in regulating rat pituitary tumor cell (GH3) growth in vitro.\n\nTulipano G, Faggi L, Cacciamali A, Spinello M, Cocchi D, Giustina A.\n\nPituitary. 2014 Jun;17(3):203-9.\n\n2015\n\n272. Parathyroid hormone pulsatility: physiological and clinical aspects.\n\nChiavistelli S, Giustina A, Mazziotti G.\n\nBone Res. 2015 Jan 27;3:14049\n\n273. Growth hormone replacement therapy and fracture risk.\n\nGiustina A, Mazziotti G.\n\nLancet Diabetes Endocrinol. 2015 May;3(5):307-8.\n\n274. Cortisol and the muscle-bone axis: response to comments by Molfino et al.\n\nScillitani A, Mazziotti G, Di Somma C, Moretti S, Stigliano A, Pivonello R, Giustina A, Colao A; ABC 2011.\n\nOsteoporos Int. 2015 May;26(5):1661-2.\n\n275. Pituitary diseases and bone.\n\nMazziotti G, Chiavistelli S, Giustina A.\n\nEndocrinol Metab Clin North Am. 2015 Mar;44(1):171-80.\n\n276. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.\n\nMelmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein MD, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger C.\n\nJ Clin Endocrinol Metab. 2015 Apr;100(4):1699-708.\n\n277. Growth hormone deficiency in treated acromegaly.\n\nMazziotti G, Marzullo P, Doga M, Aimaretti G, Giustina A.\n\nTrends Endocrinol Metab. 2015 Jan;26(1):11-21.\n\n278. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis.\n\nMazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R, Floriani I, Giustina A.\n\nJ Clin Endocrinol Metab. 2015 Feb;100(2):384-94\n\n279. Optimal use of pegvisomant in acromegaly: are we getting there?\n\nGiustina A.\n\nEndocrine. 2015 Feb;48(1):3-8.\n\n280. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.\n\nTulipano G, Faggi L, Cacciamali A, Spinello M, Cocchi D, Giustina A.\n\nJ Neuroendocrinol. 2015 Jan;27(1):20-32.\n\n281. Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor?\n\nGiustina A, Berardelli R, Gazzaruso C, Mazziotti G.\n\nActa Diabetol. 2015 Jun;52(3):433-43.\n\n2016\n\n282. Current and future medical treatments for patients with acromegaly.\n\nMaffezzoni F, Formenti AM, Mazziotti G, Frara S, Giustina A.\n\nExpert Opin Pharmacother. 2016 Jun 28:1-12.\n\n283. Current and Emerging Aspects of Diabetes Mellitus in Acromegaly.\n\nFrara S, Maffezzoni F, Mazziotti G, Giustina A.\n\nTrends Endocrinol Metab. 2016 Jul;27(7):470-83.\n\n284. Skeletal Fragility in Endogenous Hypercortisolism.\n\nMazziotti G, Delgado A, Maffezzoni F, Formenti A, Giustina A.\n\nFront Horm Res. 2016;46:66-73\n\n285. The Modern Criteria for Medical Management of Acromegaly.\n\nFrara S, Maffezzoni F, Mazziotti G, Giustina A.\n\nProg Mol Biol Transl Sci. 2016;138:63-83.\n\n286. Treatment of hypothyroidism: all that glitters is gold?\n\nFormenti AM, Mazziotti G, Giubbini R, Giustina A.\n\nEndocrine. 2016 Jun;52(3):411-3.\n\n287. Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy?\n\nMazziotti G, Maffezzoni F, Giustina A.\n\nEndocrine. 2016 May;52(2):183-6\n\n288. High prevalence of radiological vertebral fractures in adult patients with Ehlers-Danlos syndrome.\n\nMazziotti G, Dordoni C, Doga M, Galderisi F, Venturini M, Calzavara-Pinton P, Maroldi R, Giustina A, Colombi M.\n\nBone. 2016 Mar;84:88-92.\n\n289. The role of patient education in the prevention and management of type 2 diabetes: an overview.\n\nCoppola A, Sasso L, Bagnasco A, Giustina A, Gazzaruso C.\n\nEndocrine. 2016 Jul;53(1):18-27\n\n290. Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency.\n\nMazziotti G, Doga M, Frara S, Maffezzoni F, Porcelli T, Cerri L, Maroldi R, Giustina A.\n\nEndocrine. 2016 Apr;52(1):103-10.\n\n291. SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice–development and results from a pilot study.\n\nGiustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S; SAGIT Investigator Group.\n\nPituitary. 2016 Feb;19(1):39-49.\n\n292. Bone and Joint Disorders in Acromegaly.\n\nClaessen KM, Mazziotti G, Biermasz NR, Giustina A.\n\nNeuroendocrinology. 2016; 103: 86-95\n\n293. New oral anticoagulants and pituitary apoplexy.\n\nDoglietto F, Costi E, Villaret AB, Mardighian D, Fontanella MM, Giustina A.\n\nPituitary. 2016 Apr;19(2):232-4.\n\n294. Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone deficient patients\n\nMormando M, Chiloiro S, Bianchi A, Giampietro A, Angelini F, Tartaglione L, Nasto L, Milardi D, Formenti AM, Giustina A, De Marinis L\n\nClin Endocrinol 2016 Nov 85: 717-724\n\n295. High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures.\n\nMaffezzoni F, Maddalo M, Frara S, Mezzone M, Zorza I, Baruffaldi F, Doglietto F, Mazziotti G, Maroldi R, Giustina A.\n\nEndocrine. 2016 Nov;54(2):532\n\n296. New medical therapies of acromegaly.\n\nMaffezzoni F, Frara S, Doga M, Mazziotti G, Giustina A.\n\nGrowth Horm IGF Res. 2016 Oct – Dec;30-31:58-63\n\n297. Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.\n\nMazziotti G, Formenti AM, Adler RA, Bilezikian JP, Grossman A, Sbardella E, Minisola S, Giustina A.\n\nEndocrine. 2016 Dec;54(3):603-611.\n\n298. Acromegalic osteopathy.\n\nMazziotti G, Maffezzoni F, Frara S, Giustina A.\n\nPituitary. 2016 Oct 5. [Epub ahead of print]\n\n299. Erectile dysfunction as a predictor of asymptomatic coronary artery disease in elderly men with type 2 diabetes.\n\nGazzaruso C, Coppola A, Pujia A, Falcone C, Collaviti S, Fodaro M, Gallotti P, Solerte SB, Giustina A, Pelissero G, Luzi L, Montalcini T.\n\nJ Geriatr Cardiol. 2016 Sep;13(6):552-6.\n\n300. [Acromegaly: reducing diagnostic delay].\n\nGiustina A.\n\nRecenti Prog Med. 2016 Aug;107(8):450-1."
    }
}